Archived Facts

ZURICH (Reuters) – Swiss drugmaker Novartis posted worse-than-expected third quarter sales on Thursday, dragged down by the loss of a U.S. patent on its top-selling blood pressure drug Diovan and tough comparisons at its Sandoz unit.

Popular Posts:

Related Posts:

Leave a Reply